A reversed-phase high performance liquid chromatographic (RP-HPLC) method wasdeveloped and validated for the simultaneous deteimination of ceftazidime and tazobactam ininject-able powder. Methods Chromatography was ca...A reversed-phase high performance liquid chromatographic (RP-HPLC) method wasdeveloped and validated for the simultaneous deteimination of ceftazidime and tazobactam ininject-able powder. Methods Chromatography was carried out on Zorbax 300SB-C_(18) column using amixture of methanol and aqueous solution of phosphate buffer (pH = 5.6) as mobile phase. The UVdetection wavelength was 220 run. Results The linear ranges of ceftazidime and tazobactam were 0.62- 631.8 μg·mL^(-1) and 0.66 - 677.50 μg·mL^(-1), respectively. The average recoveries were 98.8%- 101.4% for ceftazidime, and 99,1% - 100.2% for tazobactam. The RSD values of inter-day andintra-day assays were lower than 1.5% for ceftazidime and 2.6% for tazobactam. Conclusion Thismethod is reproducible, simple, precise, and rapid for the quality control of ceftazidime andtazobactam in injectable powder.展开更多
Melioidosis,a disease of public health importance in Southeast Asia and Northern Australia,of late has shown an increasing trend in India,particularly Southern India.We describe a ease of a 39-year-old diabetic patien...Melioidosis,a disease of public health importance in Southeast Asia and Northern Australia,of late has shown an increasing trend in India,particularly Southern India.We describe a ease of a 39-year-old diabetic patient with left elbow septic arthritis,multiple liver,splenic abscesses, pneumonia,pleural effusion,followed by sepsis syndrome.Blood cultures and culture of the joint aspirate yielded pure growth of Burkholderia psettdomallei(B.pesudomallei),sensitive to carbapenem,co-trimoxazole and resistant to ceftazidime.The patient was successfully treated with imipenem- cilastin.He was discharged on co-trimoxazole to complete the 24 weeks course and follow-up has continued to date.The patient continues to remain asymptomatic.The case re-emphasizes the need to monitor the trend of B.pseudomallei in India,particularly the development of ceftazidime resistance,which incidentally is the drug of choice.展开更多
Objective: to compare and analyze the clinical efficacy of cefoperazone sulbactam and ceftazidime in the treatment of complicated urinary tract infections and to provide a theoretical basis for the clinical drug treat...Objective: to compare and analyze the clinical efficacy of cefoperazone sulbactam and ceftazidime in the treatment of complicated urinary tract infections and to provide a theoretical basis for the clinical drug treatment of diseases. Methods: a retrospective study of 140 patients with complicated urinary tract infections admitted to the urology department of Hu’nan Provincial Peoples Hospital from January 2017 to December 2017: cefoperazone sulbactam group (71 patients, 1.0g / bid, 2 g/d) and (69 patients, 1.5g / bid, 3g / d), and PCT, CRP. Results: more cefoperazone subactam (70 / 71,94.29%) than ceftazidime (60 / 69,84.29%) were significant (P < 0.05). A total of 19 strains were detected in the cefoperazone and sulbactam group and 33 strains in the ceftazidime group, with a significant difference in the degree of bacterial clearance in the ceftazidim group (P < 0.05). Between groups, found that the bacterial clearance rate was higher in cefoperazone sulbactam group (84.21%) than in ceftazidime group (72.73%). Plasma PCT, CRP content were decreased compared to before treatment, and the difference between the groups was significant (P < 0.05). After treatment comparison, plasma PCT(0.21±0.15ng/m L) and CRP (0.68±5.24mg/L) content in cefoperazone sulbactam group were lower than those in ceftazidime group (0.87±0.32ng/m L), (20.49±6.81mg/L), and both differences were significant (P < 0.05). The cefoperazone sulbactam group (2.73 ± 0.95 days) and the treatment cost (1078.90 ± 375.44 yuan) were less than the ceftazidime group (6.97 ± 2.25 days) and (1141.69 ± 368.55 yuan), all statistically significant (P < 0.05). The incidence of adverse reactions between cefoperazone and sulbactam (1.40%) and ceftazidime (2.89%) was not significantly different (P > 0.05), and no serious adverse drug reactions occurred. Conclusion: cefoperazone subactam has better efficacy than ceftazidime for complicated urinary tract infections, mainly in bacterial clearance, course control and treatment cost. Patients with cefoperazone subactatan treatment also have better inflammatory status control.展开更多
We present a case of keratitis caused by Stenotrophomonas maltophilia in a therapeutic contact lens user with trichiasis and symblepharon. This keratitis was initially diagnosed as caused by Achromobacter xylosoxidans...We present a case of keratitis caused by Stenotrophomonas maltophilia in a therapeutic contact lens user with trichiasis and symblepharon. This keratitis was initially diagnosed as caused by Achromobacter xylosoxidans, but the strain was sent for species confirmation and the isolate was finally identified as S. maltophilia by means of 16S rDNA sequencing. The patient rapidly improved on administration of fortified ceftazidime. Physicians should be aware that the definitive identification of the pathogenic agent and prolonged antimicrobial treatment according to culture sensitivities in keratitis are mandatory as treatment success depends greatly on them.展开更多
The antimicrobial susceptibility testing was performed with Kirby-Bauer disc diffusion and agar diffusion methods, and the crude β-lactamase was extracted by sonication with its isoelectric point （pI） determined wi...The antimicrobial susceptibility testing was performed with Kirby-Bauer disc diffusion and agar diffusion methods, and the crude β-lactamase was extracted by sonication with its isoelectric point （pI） determined with isoelectric focusing, and purified by two steps of chromatography. The genome DNA fragments of bacterial strains were amplified with PCR and subjected to sequencing. The kinetic parameters for β-lactamase were detected by spectrophoto metric method. It was found that the bacterial strains isolated from clinical specimens were resistant to penicillin, ceftazidine, cefotaxime and azitreonam, but sensitive to imipenem and cefoxitin, in which two resistant strains to ceftazidine were found to produce a single extended spectrum β-lactamase（ESBL） with pI value of 8.7. Results of cloning and sequencing of the β-lactamase encoding gene showed that this gene was similar to blactx-m-l with 6 point mutations including 3 silent mutations. The amino acid sequence derived from the nucleic acid data indicated that this enzyme was distinct from β-lactamse CTX-M-1 by 3 amino acids, i.e. Val-80→Ala, Asp-117→Asn and Ser-143→Ala（CTX-M-Ⅳ）. Molecular weight of this enzyjne was 29 kDa. Kinetic analysis of the partially purified β-lactamase confirmed that this enzyine was ＇able to hydrolyze cefotaxime and aztreonanl, but not to imipenem. In addition, the the β-lactamase was well inhibited by sulbactam（IC50 94 nM） and tazobactam（IC50 5 nM）. It is concluded that CTX-M-Ⅳ is a CTX-M-type extended spectrum β-lactamase.展开更多
文摘A reversed-phase high performance liquid chromatographic (RP-HPLC) method wasdeveloped and validated for the simultaneous deteimination of ceftazidime and tazobactam ininject-able powder. Methods Chromatography was carried out on Zorbax 300SB-C_(18) column using amixture of methanol and aqueous solution of phosphate buffer (pH = 5.6) as mobile phase. The UVdetection wavelength was 220 run. Results The linear ranges of ceftazidime and tazobactam were 0.62- 631.8 μg·mL^(-1) and 0.66 - 677.50 μg·mL^(-1), respectively. The average recoveries were 98.8%- 101.4% for ceftazidime, and 99,1% - 100.2% for tazobactam. The RSD values of inter-day andintra-day assays were lower than 1.5% for ceftazidime and 2.6% for tazobactam. Conclusion Thismethod is reproducible, simple, precise, and rapid for the quality control of ceftazidime andtazobactam in injectable powder.
文摘Melioidosis,a disease of public health importance in Southeast Asia and Northern Australia,of late has shown an increasing trend in India,particularly Southern India.We describe a ease of a 39-year-old diabetic patient with left elbow septic arthritis,multiple liver,splenic abscesses, pneumonia,pleural effusion,followed by sepsis syndrome.Blood cultures and culture of the joint aspirate yielded pure growth of Burkholderia psettdomallei(B.pesudomallei),sensitive to carbapenem,co-trimoxazole and resistant to ceftazidime.The patient was successfully treated with imipenem- cilastin.He was discharged on co-trimoxazole to complete the 24 weeks course and follow-up has continued to date.The patient continues to remain asymptomatic.The case re-emphasizes the need to monitor the trend of B.pseudomallei in India,particularly the development of ceftazidime resistance,which incidentally is the drug of choice.
文摘Objective: to compare and analyze the clinical efficacy of cefoperazone sulbactam and ceftazidime in the treatment of complicated urinary tract infections and to provide a theoretical basis for the clinical drug treatment of diseases. Methods: a retrospective study of 140 patients with complicated urinary tract infections admitted to the urology department of Hu’nan Provincial Peoples Hospital from January 2017 to December 2017: cefoperazone sulbactam group (71 patients, 1.0g / bid, 2 g/d) and (69 patients, 1.5g / bid, 3g / d), and PCT, CRP. Results: more cefoperazone subactam (70 / 71,94.29%) than ceftazidime (60 / 69,84.29%) were significant (P < 0.05). A total of 19 strains were detected in the cefoperazone and sulbactam group and 33 strains in the ceftazidime group, with a significant difference in the degree of bacterial clearance in the ceftazidim group (P < 0.05). Between groups, found that the bacterial clearance rate was higher in cefoperazone sulbactam group (84.21%) than in ceftazidime group (72.73%). Plasma PCT, CRP content were decreased compared to before treatment, and the difference between the groups was significant (P < 0.05). After treatment comparison, plasma PCT(0.21±0.15ng/m L) and CRP (0.68±5.24mg/L) content in cefoperazone sulbactam group were lower than those in ceftazidime group (0.87±0.32ng/m L), (20.49±6.81mg/L), and both differences were significant (P < 0.05). The cefoperazone sulbactam group (2.73 ± 0.95 days) and the treatment cost (1078.90 ± 375.44 yuan) were less than the ceftazidime group (6.97 ± 2.25 days) and (1141.69 ± 368.55 yuan), all statistically significant (P < 0.05). The incidence of adverse reactions between cefoperazone and sulbactam (1.40%) and ceftazidime (2.89%) was not significantly different (P > 0.05), and no serious adverse drug reactions occurred. Conclusion: cefoperazone subactam has better efficacy than ceftazidime for complicated urinary tract infections, mainly in bacterial clearance, course control and treatment cost. Patients with cefoperazone subactatan treatment also have better inflammatory status control.
文摘We present a case of keratitis caused by Stenotrophomonas maltophilia in a therapeutic contact lens user with trichiasis and symblepharon. This keratitis was initially diagnosed as caused by Achromobacter xylosoxidans, but the strain was sent for species confirmation and the isolate was finally identified as S. maltophilia by means of 16S rDNA sequencing. The patient rapidly improved on administration of fortified ceftazidime. Physicians should be aware that the definitive identification of the pathogenic agent and prolonged antimicrobial treatment according to culture sensitivities in keratitis are mandatory as treatment success depends greatly on them.
文摘The antimicrobial susceptibility testing was performed with Kirby-Bauer disc diffusion and agar diffusion methods, and the crude β-lactamase was extracted by sonication with its isoelectric point （pI） determined with isoelectric focusing, and purified by two steps of chromatography. The genome DNA fragments of bacterial strains were amplified with PCR and subjected to sequencing. The kinetic parameters for β-lactamase were detected by spectrophoto metric method. It was found that the bacterial strains isolated from clinical specimens were resistant to penicillin, ceftazidine, cefotaxime and azitreonam, but sensitive to imipenem and cefoxitin, in which two resistant strains to ceftazidine were found to produce a single extended spectrum β-lactamase（ESBL） with pI value of 8.7. Results of cloning and sequencing of the β-lactamase encoding gene showed that this gene was similar to blactx-m-l with 6 point mutations including 3 silent mutations. The amino acid sequence derived from the nucleic acid data indicated that this enzyme was distinct from β-lactamse CTX-M-1 by 3 amino acids, i.e. Val-80→Ala, Asp-117→Asn and Ser-143→Ala（CTX-M-Ⅳ）. Molecular weight of this enzyjne was 29 kDa. Kinetic analysis of the partially purified β-lactamase confirmed that this enzyine was ＇able to hydrolyze cefotaxime and aztreonanl, but not to imipenem. In addition, the the β-lactamase was well inhibited by sulbactam（IC50 94 nM） and tazobactam（IC50 5 nM）. It is concluded that CTX-M-Ⅳ is a CTX-M-type extended spectrum β-lactamase.
